ClinicalTrials.gg
RecruitingNCT07851220MOMENTUpdated Oct 1, 2026

A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy

A Phase 3 interventional study of Inebilizumab and Tacrolimus in Glomerulonephritis, Membranous, sponsored by Amgen. Recruiting at 4 sites in United States. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 35 studies in Glomerulonephritis, Membranous with a site in United States — 13 open to participants now, 16 under way, 5 of them phase 3. Glomerulonephritis, Membranous · United States.

Planned enrollment
5th of 32
159 · median 31
Started
2026
with 3 others
Phase 3
3 of 35
2 open now
Primary completion
2031-09
later than 14 of 15 live
Registered
34th of 35
by date
Lead sponsor
1 of 35
Amgen

Among the 35 studies in Glomerulonephritis, Membranous with a site in United States, this one is the 5th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 3, reaches primary completion later than 14 of the 15 other live ones, and was the 34th registered.

Glomerulonephritis, Membranous

146 studies on the registry are indexed under Glomerulonephritis, Membranous; 60 are open to participants now.

Browse Glomerulonephritis, Membranous studies →

Open to participants now

13 of the 35 studies in Glomerulonephritis, Membranous with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Glomerulonephritis, Membranous studies recruiting now, 14 (34%) set no upper age limit and 14 (34%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Glomerulonephritis, Membranous with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.

03

Conditions studied

  • Glomerulonephritis, Membranous

Keywords

  • Inebilizumab
  • AMG 335
  • Uplizna
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged ≥18 years and \<80 years.
  • Able and willing to provide written .
  • Primary membranous nephropathy (PMN) confirmed by renal (performed during screening or within 5 years before screening), or biopsy exemption for participants with anti-PLA2R antibody ≥20 RU/mL at screening.
  • Participants with diabetes (HbA1c) \<7.5% require a renal biopsy report within 2 years before screening (or biopsy during screening) demonstrating PMN without diabetic nephropathy.
  • Urine protein-to-creatinine ratio (UPCR) ≥3.5 from a 24-hour urine collection at screening.
  • Receiving a maximally tolerated Angiotensin-Converting Enzyme (ACE) inhibitor or (Angiotensin II receptor blocker) ARB for ≥3 months before randomization with adequately controlled blood pressure (\<140/90 mmHg).

Exclusion criteria

Exclusion Criteria:

  • Secondary membranous nephropathy (e.g., due to disease, infection, , or medications).
  • Estimated (eGFR) \<40 mL/min/1.73 m\^2 , ≥30% decline in eGFR during the previous 24 weeks, need for dialysis, kidney replacement therapy, kidney transplant, or planned transplant during the study.
  • Recent thromboembolic event (within 3 months).
  • Active , infection, Hepatitis B surface antigen (HBsAg) positive, active infection, uncontrolled diabetes ( ≥7.5%), active or inadequately treated tuberculosis, recurrent herpes zoster or opportunistic infections, active infection, recurrent serious infections, or immunodeficiency disorders.
  • Clinically significant laboratory abnormalities, including severe anemia, neutropenia, thrombocytopenia, low Cluster of Differentiation (CD19+) B-cell count, hepatic dysfunction, or immunoglobulin G (IgG) \<400 mg/dL.
  • History of solid organ or cell transplantation or progressive multifocal leukoencephalopathy.
  • Recent treatment with prohibited therapies, including: B-cell-depleting biologics or other biologic immunomodulators, calcineurin inhibitors, alkylating agents within 3 months;( except history of resistance to calcineurin inhibitors); other agents within 4 weeks; within 1 month, or live or (within 4 weeks before randomization).

Note: Other protocol-defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
159 participants (estimated)

Study arms

  • Experimental
    Inebilizumab

    Participants will receive inebilizumab via intravenous (IV) infusion

    Drug: Inebilizumab

  • Active comparator
    Tacrolimus

    Participants will receive tacrolimus orally.

    Drug: Tacrolimus

Interventions

  • Inebilizumab will be administered via IV infusion.

    Also known as: AMG 335 / Uplizna

  • Tacrolimus will be administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Complete Remission at Week 104

    Time frame: At Week 104

Secondary outcomes

  1. Percentage of Participants Achieving Complete Remission or Partial Remission at Week 104

    Time frame: At Week 104

  2. Percentage of Participants Achieving Complete Remission or Partial Remission at Week 78

    Time frame: At Week 78

  3. Percentage of Participants Achieving Complete Remission at Week 78

    Time frame: At Week 78

  4. Time to First Complete Remission by Week 104

    Time frame: Up to Week 104

  5. Time to First Complete Remission or Partial Remission by Week 104

    Time frame: Up to Week 104

  6. Duration of Complete Remission in the Inebilizumab Arm

    Time frame: Up to Week 104

  7. Percentage Change from Baseline in Anti-Phospholipase A2 Receptor (PLA2R) Antibody Levels in Anti-PLA2R Positive Participants at Week 26

    Time frame: From Baseline to Week 26

  8. Number of Participants who Experienced Treatment-emergent Adverse Events, Treatment-emergent Serious Adverse Events, and Treatment-emergent Adverse Events of Interest

    Time frame: Up to Week 194

  9. Number of Participants who Develop Anti-inebilizumab Antibodies

    Time frame: Up to Week 104

  10. Serum Concentrations of Inebilizumab

    Time frame: Up to Week 160

  11. Percentage Change from Baseline in Anti-PLA2R Antibody Levels at Week 78 and Week 104

    Time frame: From Baseline to Week 78 and Week 104

  12. Time to First Relapse

    Time frame: From Day 1 to Week 104

  13. Time to Initiate First Rescue Treatment

    Time frame: From day 1 to Week 104

  14. Change From Baseline in Kidney Disease Quality of Life (KDQoL)-36 Domain Scores at Week 78 and at Week 104

    Time frame: From Baseline to Week 78 and Week 104

  15. Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue 7a Score at Week 78 and at Week 104

    Time frame: From Baseline to Week 78 and Week 104

  16. Change from baseline in the Estimated Glomerular Filtration Rate (eGFR)

    Time frame: From Baseline to Week 78 and Week 104

  17. Percentage of Participants Achieving Stabilized eGFR at week 104, with a Decrease of ≤15 % From Baseline

    Time frame: From Baseline to Week 104

07

Study locations

4 of 4 sites recruiting
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
    Recruiting
  • Bioresearch Partner-Jackson West
    Doral, Florida 33122, United States
    Recruiting
  • Bioresearch Partner- Martin Luther King Jr.
    Miami, Florida 33127, United States
    Recruiting
  • Bioresearch Partner- Pembroke Pines
    Pembroke Pines, Florida 33029, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · wwwext.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Sep 2031, 59 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 1, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Sep 27, 2031
CompletionEst.
Sep 26, 2033
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851220
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 27, 2031 (estimated)
Completion
Sep 26, 2033 (estimated)
Last update
Oct 1, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inebilizumab

Start the discussion